All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Gender, female Gender, male metastasis (bone) PD-L1 < 1% PD-L1 > 1% PD-L1 > 5% previous nephrectomy (no) previous nephrectomy (yes) Risk favorable (IMDC) Risk intermediate (IMDC) Risk poor (IMDC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
renal cell cancer (RCC), nivolumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 025, 2015 0.73 [0.57; 0.93]
CheckMate 9ER, 2021 0.60 [0.40; 0.89]
0.69 [0.56 ; 0.85 ] CheckMate 025, 2015, CheckMate 9ER, 2021 2 0% 1,472 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 9ER, 2021 0.70 [0.55; 0.90]
0.70 [0.55 ; 0.90 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable PFS (extension)detailed results CheckMate 9ER, 2021 0.56 [0.46; 0.68]
0.56 [0.46 ; 0.68 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable progression or deaths (PFS)detailed results CheckMate 025, 2015 0.88 [0.75; 1.03]
CheckMate 9ER, 2021 0.51 [0.41; 0.64]
0.67 [0.39 ; 1.15 ] CheckMate 025, 2015, CheckMate 9ER, 2021 2 93% 1,472 moderate not evaluable objective responses (ORR)detailed results CheckMate 025, 2015 5.98 [3.68; 9.72]
CheckMate 9ER, 2021 3.38 [2.44; 4.69]
4.37 [2.50 ; 7.61 ] CheckMate 025, 2015, CheckMate 9ER, 2021 2 73% 1,472 moderate not evaluable objective responses (ORR) (extension)detailed results CheckMate 9ER, 2021 3.18 [2.30; 4.40]
3.18 [2.30 ; 4.40 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable TRAE (any grade)detailed results CheckMate 025, 2015 0.50 [0.34; 0.74]
CheckMate 9ER, 2021 2.14 [1.02; 4.46]
1.00 [0.24 ; 4.12 ] CheckMate 025, 2015, CheckMate 9ER, 2021 2 91% 1,454 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.40 [0.29; 0.55]
0.40 [0.29 ; 0.55 ] CheckMate 025, 2015 1 0% 803 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 025, 2015 0.24 [0.01; 5.42]
CheckMate 9ER, 2021 0.51 [0.05; 5.61]
0.38 [0.06 ; 2.57 ] CheckMate 025, 2015, CheckMate 9ER, 2021 2 0% 1,454 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 025, 2015 0.55 [0.34; 0.88]
CheckMate 9ER, 2021 1.84 [1.13; 3.00]
1.00 [0.31 ; 3.29 ] CheckMate 025, 2015, CheckMate 9ER, 2021 2 92% 1,454 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.21 [0.09; 0.48]
0.21 [0.09 ; 0.48 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.49 [0.09; 2.67]
0.49 [0.09 ; 2.67 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.28; 3.40]
0.98 [0.28 ; 3.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 025, 2015 1.47 [0.24; 8.85]
1.47 [0.24 ; 8.85 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.89 [0.37; 2.11]
0.89 [0.37 ; 2.11 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.04 [0.00; 0.67]
0.04 [0.00 ; 0.67 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.32 [0.03; 3.13]
0.32 [0.03 ; 3.13 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.53 [0.19; 1.44]
0.53 [0.19 ; 1.44 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.65 [0.11; 3.91]
0.65 [0.11 ; 3.91 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.03 [0.00; 0.46]
0.03 [0.00 ; 0.46 ] CheckMate 025, 2015 1 0% 803 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-20 20:17 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 10,93,79,178,152,80
- treatments: 855,360,719,721,720,842,642,674,1085,863
